| Trial ID: | L6105 |
| Source ID: | NCT06759922
|
| Associated Drug: |
Tab Metformin + Tab Glimepiride
|
| Title: |
Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Tab Metformin + Tab Glimepiride|DRUG: Tab Metformin + Tab Empagliflozin|DRUG: Tab Metformin +Tab Sitagliptin|DRUG: Tab Metformin + Tab Empagliflozin + Tab Sitagliptin
|
| Outcome Measures: |
Primary: Primary Outcome, Change in HbA1c levels in %, 3 months | Secondary: Secondary Outcome, 1. Change in BMI (weight and height will be combined to report BMI in kg/m\^2) 2. Change in Lipid Profile in mg/dL 3. Incidence of Treatment-Emergent Adverse Events Metformin (Diarrhea) Glimepiride (Weight gain, Hypoglycemia) Empagliflozin (Urinary incontinence, Genitourinary infections) Sitagliptin (Gastrointestinal symptoms, Pancreatitis, Upper respiratory tract infections), 3months
|
| Sponsor/Collaborators: |
Sponsor: Bahria University
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
172
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2025-01-01
|
| Completion Date: |
2025-06-30
|
| Results First Posted: |
|
| Last Update Posted: |
2025-02-06
|
| Locations: |
National Medical Center, Karachi, Sindh, 75500, Pakistan
|
| URL: |
https://clinicaltrials.gov/show/NCT06759922
|
